Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Orthometrix, Inc. (OMRX)
Naples, FL, US
Orthometrix, Inc., founded in 1993 and based in Naples, Florida, specializes in developing and distributing advanced technologies, methods, and devices aimed at enhancing musculoskeletal mobility. The company also focuses on providing non-invasive solutions to manage pain linked to conditions like osteoarthritis, plantar fasciitis, and other musculoskeletal issues that impede movement. Their product line encompasses a variety of offerings: Peripheral quantitative computed tomography (pQCT) systems, used for detailed bone and muscle measurement in both clinical and research environments. Patented motorized exercise systems, featuring unique vibration technology, designed for rehabilitation, physical therapy, and sports medicine applications. These are marketed to professional sports teams, fitness facilities, and the wellness-conscious public. Human performance measurement systems, which help track improvements in power and overall mobility. Extracorporeal shock wave therapy (ESWT) systems, offering non-invasive treatment for plantar fasciitis discomfort. Orthometrix provides sales and servicing for its range of products, which fall into categories such as bone and muscle diagnostics, research equipment, rehabilitation/physical therapy tools, sports and fitness gear, and home-use products. They serve a broad client base across the healthcare, veterinary, and sports & fitness sectors, both domestically in the United States and internationally. The company was previously known as Norland Medical Systems, Inc. before officially changing its name to Orthometrix, Inc. in April 2002.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -98.59% | -98.48% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+42.7% ★ Q3'08: -82.1% (vs Q3'07)
-
EPS growth Medical - Specialties: +10.1%+609.1% ★ Q3'08: -212.5% (vs Q3'07)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+35.1% ★ Q3'08: -128.3% (vs Q3'07)
-
EBIT margin Medical - Specialties: +12.6%+31.7% ★ Q3'08: -184.6% (vs Q3'07)
-
ROIC Medical - Specialties: +6.6%—
-
Share dilution Medical - Specialties: 0.0%+0.4% Q3'08: +9.7% (vs Q3'07)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×1.16× Q3'08: -3.45× (vs Q3'07)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Reynald G. Bonmati | Founder, Chief Executive Officer, President, Treasurer and Chairman of the Board | 1.7K | male |
| Arik Avni | Chief Technical Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OMRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
